President Lai Ching-te affirmed the achievements of Taiwan’s biomedical industry and announced that the National Development Fund would invest 10 billion yuan to support industrial upgrading.

President Lai Ching-te said today that the turnover of Taiwan's biomedical industry reached NT$830.1 billion last year, and a number of domestically produced new drugs and innovative medical materials have obtained international certification. The government has also increased resource support. The National Development Fund has passed the "Implementation Plan for Investment in Taiwan's Biomedical Industry" this year, allocating NT$10 billion over a 10-year period to help companies move from research and development to productization and commercialization, allowing Taiwan to move more steadily and further in the development of the global biomedical industry.

Lai Qingde met with the winners of the "115 Annual Outstanding Biotechnology Industry Award" today and thanked them for their long-term investment in research and development, accumulation of technological energy, and step by step improvement of Taiwan's international competitiveness. Last year, the turnover of Taiwan's biomedical industry reached NT$830.1 billion, and a number of domestically produced new drugs and innovative medical materials have obtained international certification and are gradually entering the global market. It is expected that the Biopharmaceutical Association will continue to serve as an important industry platform and communication bridge, helping more research and development results to integrate with international standards and flourish at home and abroad.

Please read on...

Lai Ching-te said that with the restructuring of the global supply chain and the changes in the economic and trade order brought about by tariffs in recent years, the biomedical industry is facing new challenges. Now is an important moment for Taiwan to strengthen its own strength and improve the resilience of the industry. The government will continue to be the strongest backing for the industry in terms of policies, regulations, technology, and funds.

Lai Qingde pointed out that the dual laws on regenerative medicine have been put into effect this year. The government has strengthened safety and quality management through special laws and accelerated the clinical application of research and development results. The implementation of the "National Health Insurance Data Management Regulations" has also provided clearer regulations for the use of National Health Insurance data on the premise of protecting privacy.

Lai Ching-te said that the government continues to integrate AI, semiconductors, big data and biomedical industries, leveraging Taiwan's existing scientific and technological advantages to promote the development of smart medicine, precision medicine and new generation medical technology. In terms of resource support, in August this year, the National Development Fund Management Committee passed the "Implementation Plan for Investment in Taiwan's Biomedical Industry", allocating 10 billion yuan for 10 years to support the development of the biomedical industry and assist companies from research and development to productization and commercialization.

The president said that for him, who is a physician, the most important value of the biomedical industry is to provide more technologies and products that can truly respond to the needs of medical sites and bring better medical care and healthy lives to the Chinese people. We hope that these achievements can be turned into international competitiveness, allowing Taiwan to advance more steadily and further in the development of the global biomedical industry.